Axios - The list price of new drugs approved by the FDA increased by a median of 24% between 2022 and 2024, and the median net price increased by 51%, according to a report released yesterday by the Institute for Clinical and Economic Review.
- In other words, the actual price paid for new drugs — net rebates and discounts — rose even more than list prices did over that three-year period.
- Even when accounting for differences in the mix of drugs approved each year, the annual net launch price increased by 33% per year. More
No comments:
Post a Comment